CA3228345A1 - Camptothecin derivative, and pharmaceutical composition and use thereof - Google Patents

Camptothecin derivative, and pharmaceutical composition and use thereof Download PDF

Info

Publication number
CA3228345A1
CA3228345A1 CA3228345A CA3228345A CA3228345A1 CA 3228345 A1 CA3228345 A1 CA 3228345A1 CA 3228345 A CA3228345 A CA 3228345A CA 3228345 A CA3228345 A CA 3228345A CA 3228345 A1 CA3228345 A1 CA 3228345A1
Authority
CA
Canada
Prior art keywords
compound
reaction solution
added
stirred
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228345A
Other languages
English (en)
French (fr)
Inventor
Zhen Li
Feng Tang
Yayuan FU
Lifeng Liu
Chunyan ZHAO
Renhong TANG
Jinsheng Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Simcere Zaiming Pharmaceutical Co Ltd
Original Assignee
Simcere Zaiming Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simcere Zaiming Pharmaceutical Co Ltd filed Critical Simcere Zaiming Pharmaceutical Co Ltd
Publication of CA3228345A1 publication Critical patent/CA3228345A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3228345A 2021-08-19 2022-08-19 Camptothecin derivative, and pharmaceutical composition and use thereof Pending CA3228345A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110955364.5 2021-08-19
CN202110955364 2021-08-19
CN202111515247 2021-12-13
CN202111515247.3 2021-12-13
CN202210515797.3 2022-05-12
CN202210515797 2022-05-12
PCT/CN2022/113499 WO2023020605A1 (zh) 2021-08-19 2022-08-19 喜树碱衍生物、其药物组合物及其应用

Publications (1)

Publication Number Publication Date
CA3228345A1 true CA3228345A1 (en) 2023-02-23

Family

ID=85239565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228345A Pending CA3228345A1 (en) 2021-08-19 2022-08-19 Camptothecin derivative, and pharmaceutical composition and use thereof

Country Status (8)

Country Link
US (1) US20250270227A1 (https=)
EP (1) EP4389752A4 (https=)
JP (1) JP2024532768A (https=)
KR (1) KR20240049583A (https=)
CN (1) CN117769555A (https=)
AU (1) AU2022330892A1 (https=)
CA (1) CA3228345A1 (https=)
WO (1) WO2023020605A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
KR20240149823A (ko) * 2023-04-06 2024-10-15 주식회사 피노바이오 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
CN120858098A (zh) * 2023-05-04 2025-10-28 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
WO2024227439A1 (zh) * 2023-05-04 2024-11-07 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
WO2025153001A1 (zh) * 2024-01-17 2025-07-24 北京泰德制药股份有限公司 含有噻唑[5,4-b]吡啶结构的抗体偶联药物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540099B1 (en) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
CN1036197C (zh) * 1992-01-28 1997-10-22 格拉克索有限公司 水溶性喜树碱衍生物
JPH1171280A (ja) * 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TWI851577B (zh) * 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
EP4628165A3 (en) * 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
EP4257154A4 (en) * 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
IL308734A (en) * 2021-05-27 2024-01-01 Zymeworks Bc Inc Camptothecin analogues, conjugates and methods of use
US20240376120A1 (en) * 2021-09-01 2024-11-14 Shanghai Best-Link Bioscience, Llc Camptothecin compound, preparation method therefor and use thereof
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用

Also Published As

Publication number Publication date
US20250270227A1 (en) 2025-08-28
AU2022330892A1 (en) 2024-03-21
EP4389752A4 (en) 2025-08-20
CN117769555A (zh) 2024-03-26
JP2024532768A (ja) 2024-09-10
WO2023020605A1 (zh) 2023-02-23
KR20240049583A (ko) 2024-04-16
EP4389752A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
CA3228345A1 (en) Camptothecin derivative, and pharmaceutical composition and use thereof
AU2019413360B2 (en) Cyclin-dependent kinase inhibitors
ES2402791T3 (es) Forma cristalina de la sal diclorhidrato de ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
DK2719699T3 (en) Triazolopyraziner particular, compositions thereof and methods of use thereof
CN104640858B (zh) 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法
WO2024002373A1 (zh) 取代嘧啶并环类抑制剂及其制备方法和应用
CN116199703A (zh) 稠合四环杂环化合物、其制备方法及其在医药上的应用
EP2739618B1 (en) Quinazoline compounds as serine/threonine kinase inhibitors
AU2020200407A1 (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
CN114716435A (zh) Kras g12c突变抑制剂
CN105461714B (zh) 并环类pi3k抑制剂
CN109789143A (zh) 基于嘧啶的抗增殖剂
KR102464677B1 (ko) 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
CA2987993A1 (en) Gadolinium chelate compounds for use in magnetic resonance imaging
UA130084C2 (uk) Імідазопіримідини як інгібітори eed і їх застосування
WO2017080966A1 (en) Tetrahydronaphthalene estrogen receptor modulators and uses thereof
EP3373932A1 (en) Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
WO2016210247A1 (en) New methods of use for an anti-diarrhea agent
TWI415613B (zh) Anti-cancer agent resistance to overcome the agent
CN116209662A (zh) Rip1k抑制剂
KR20250091232A (ko) 피페리디노피리미딘계 유도체, 이의 제조 방법 및 이의 의학적 응용
CN114667288A (zh) 苯并菲啶生物碱及其使用方法
CN111039947A (zh) 一类蛋白受体激酶抑制剂的制备和应用
HK40107233A (en) Camptothecin derivative, and pharmaceutical composition and use thereof
WO2020247679A1 (en) Wdr5 inhibitors and modulators

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250725

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260311